‘Decentralized clinical trial delivery in SaaS raises buyback rates’ / Youngyong Park, CTO
JNPMEDI
“The cost of introducing a built-in solution during clinical trials is a concern for biotech. We offer software as a service (SaaS) and pay-as-you-go options for ease of access by small and medium-sized businesses”
Youngyong Park, JNPMEDI CTO
JNPMEDI develops and offers its own clinical trial data management platform ‘Maven Clinical Cloud’ solution. By developing software (SW) that digitally enables clinical trials, JNPMEDI systematically manages the pleathora of data generated during clinical trials, which are essential for the development of new drugs or medical devices. The only company in Korea that offers distributed clinical trials (DCTs) on a SaaS basis without installation is JNPMEDI, and it is quickly gaining traction with clinical trials stakeholders such as hospitals, Contract Research Organizations (CROs) and pharma/biopharma companies. Youngyong Park, the Chief Technology Officer (CTO) of JNPMEDI, said in an interview, “This year’s sales, backed by the increased repurchase rates from existing customers, will grow more than 500% year-on-year.”
JNPMEDI has recently introduced a pharmacovigilance solution, ‘Maven Safety”. As a result, the "Maven Clinical Cloud" platform provides clinical trial data, document, DCT, data collection, and safety management in Maven CDMS, Maven Docs, Maven DCT Suite, Maven eCOA, and Maven Safety respectively.
Maven Clinical Cloud will provide an end-to-end clinical trial ecosystem in which a client can manage the entirety of a clinical trial with one solution in a lean fashion to fit the design or shape of each trial.